PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 17, 2026S S Korsakov Journal of Neurology and Psychiatry0 citations

Features of brain involvement in tuberous sclerosis patients in the Republic of Bashkortostan

View Full Paper
RMR.N. Mustafin

Key Points

  • The study aims to identify brain involvement and genetic causes of tuberous sclerosis in patients from Bashkortostan.
  • Retrospective analysis of patient data from 2012 to 2025
  • Evaluation of genetic mutations in TSC1 and TSC2 genes
  • Assessment of prevalence and clinical features of tuberous sclerosis
  • Prevalence of tuberous sclerosis in Bashkortostan is 2.12 per 100,000 population
  • Subependymal giant cell astrocytoma found in 19% of patients
  • Cognitive deficits present in 47% of patients
  • Mutations in TSC1 and TSC2 genes were identified, with various mutation types

Abstract

Objective. To identify the features of brain involvement and to characterize the genetic causes of tuberous sclerosis (TS) in patients in the Republic of Bashkortostan. Material and methods. A retrospective analysis of data on patients with TS registered with geneticists of the Republican Medical Genetic Center for the period from 2012 to 2025 was performed. Results. The prevalence of TS in the republic was 2.12 per 100.000 population. Subependymal giant cell astrocytoma was detected in 19%, epilepsy in 67%, subependymal hamartomas in 66%, and cortical tubers in 43% of patients. Cognitive deficits were present in 47% of patients, while autism spectrum disorders were found in only 1%. Mutations were identified in the TSC1 gene in 5 patients, the TSC2 gene in 19 patients, and extended deletions of the TSC2 gene in 4 patients. Discussion. TS prevalence in the region is 5.24 times lower than the global average. The frequencies of cortical tubers, subependymal nodes, cognitive deficits, and autism spectrum disorders are also significantly lower than those reported in international meta-analyses. No data were available on behavioral disorders or attention-deficit hyperactivity disorder. Five TSC1 gene mutations (three de novo) and 19 TSC2 gene mutations (one de novo) were reported. Eight patients received targeted therapy. Conclusion. Raising awareness of TS among physicians in all specialties is essential to ensure comprehensive case reporting. Genetic confirmation of TS enables effective treatment with mTOR inhibitors. All TS patients should consult a psychiatrist and psychologist for the diagnosis and management of intellectual disability, autism spectrum disorders, and behavioral disorders.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

R.N. Mustafin (2026) studied this question.

synapsesocial.com/papers/69e1ce3b5cdc762e9d8574edhttps://doi.org/10.17116/jnevro202612603181
Ask AI
Helpful
Bookmark
Share
View Full Paper